Stock Track | Dr Reddy's Laboratories Plummets 5.41% on Earnings Miss and Trump Tariff Concerns

Stock Track

07/22

Dr Reddy's Laboratories (NYSE:RDY) saw its shares plummet 5.41% during intraday trading on Wednesday, as the stock was hit by disappointing quarterly results and broader sector concerns over proposed U.S. tariffs on generic medicines.

The pharmaceutical company reported first-quarter earnings that significantly missed analyst estimates, with EPS of $0.06 falling 64.71% below the $0.17 consensus. Quarterly sales of $853 million also missed expectations by 7.84% and represented a 14.44% decrease from the same period last year.

Compounding the company-specific issues, shares in generic-drug makers across Asia and Europe declined after former President Donald Trump announced plans to impose a 100% tariff on such drugs starting in August 2028. Analysts noted the plan would hit predominantly China and India, where most generic drugs are manufactured, putting pressure on companies like Dr Reddy's that operate on thinner margins.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1176509502"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176509502\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176509502?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 21:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176509502","market":"us","top_or_hot":-1,"title":"Stock Track | Dr Reddy's Laboratories Plummets 5.41% on Earnings Miss and Trump Tariff Concerns","media":"Stock Track","content":"<p>Dr Reddy's Laboratories (NYSE:RDY) saw its shares plummet 5.41% during intraday trading on Wednesday, as the stock was hit by disappointing quarterly results and broader sector concerns over proposed U.S. tariffs on generic medicines.</p><p>The pharmaceutical company reported first-quarter earnings that significantly missed analyst estimates, with EPS of $0.06 falling 64.71% below the $0.17 consensus. Quarterly sales of $853 million also missed expectations by 7.84% and represented a 14.44% decrease from the same period last year.</p><p>Compounding the company-specific issues, shares in generic-drug makers across Asia and Europe declined after former President Donald Trump announced plans to impose a 100% tariff on such drugs starting in August 2028. Analysts noted the plan would hit predominantly China and India, where most generic drugs are manufactured, putting pressure on companies like Dr Reddy's that operate on thinner margins.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Dr Reddy's Laboratories Plummets 5.41% on Earnings Miss and Trump Tariff Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Dr Reddy's Laboratories Plummets 5.41% on Earnings Miss and Trump Tariff Concerns\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-07-22 21:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Dr Reddy's Laboratories (NYSE:RDY) saw its shares plummet 5.41% during intraday trading on Wednesday, as the stock was hit by disappointing quarterly results and broader sector concerns over proposed U.S. tariffs on generic medicines.</p><p>The pharmaceutical company reported first-quarter earnings that significantly missed analyst estimates, with EPS of $0.06 falling 64.71% below the $0.17 consensus. Quarterly sales of $853 million also missed expectations by 7.84% and represented a 14.44% decrease from the same period last year.</p><p>Compounding the company-specific issues, shares in generic-drug makers across Asia and Europe declined after former President Donald Trump announced plans to impose a 100% tariff on such drugs starting in August 2028. Analysts noted the plan would hit predominantly China and India, where most generic drugs are manufactured, putting pressure on companies like Dr Reddy's that operate on thinner margins.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RDY","symbol_name":"如瑞迪博士","start_time":0,"source_url":"","article_id":"1176509502","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176509502","pubTimestamp":1784727158,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Dr Reddy's Laboratories (NYSE:RDY) saw its shares plummet 5.41% during intraday trading on Wednesday, as the stock was hit by disappointing quarterly results and broader sector concerns over proposed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RDY":"如瑞迪博士"},"translate_title":"股票跟踪 | Dr Reddy's Laboratories 因盈利低迷和特朗普关税担忧暴跌 5.41%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDY":1},"content_text":"Dr Reddy's Laboratories (NYSE:RDY) saw its shares plummet 5.41% during intraday trading on Wednesday, as the stock was hit by disappointing quarterly results and broader sector concerns over proposed U.S. tariffs on generic medicines.The pharmaceutical company reported first-quarter earnings that significantly missed analyst estimates, with EPS of $0.06 falling 64.71% below the $0.17 consensus. Quarterly sales of $853 million also missed expectations by 7.84% and represented a 14.44% decrease from the same period last year.Compounding the company-specific issues, shares in generic-drug makers across Asia and Europe declined after former President Donald Trump announced plans to impose a 100% tariff on such drugs starting in August 2028. Analysts noted the plan would hit predominantly China and India, where most generic drugs are manufactured, putting pressure on companies like Dr Reddy's that operate on thinner margins.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}